Aktienanalyse zu GSK plc (GSK)GSKGSK plc

GSK plc is a United Kingdom-based biopharma company. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its segments include Commercial Operations and Research and Development. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) to antibiotics. It also owns ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody and HS235, a potential molecule for the treatment of pulmonary hypertension (PH). Its oncology portfolio also includes Zidesamtinib (NVL-520), neladalkib (NVL-655), and NVL-330. Its products include Anoro Ellipta, Apretude, Arexvy, Bexsero, Blenrep, Blujepa, Boostrix, Cervarix, Dovato, Efimosfermin, among others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

GSK plc is a good buy right now due to its current price of 49.51, which is below the average analyst price target of approximately 2,100 GBp (about 52.73 USD). The stock has shown a strong 5-day change of +6.47%, indicating positive momentum, and a forward P/E ratio of 9.77 suggests it is undervalued compared to its earnings potential. However, the RSI is at 73.13, indicating it may be overbought, which is a risk to consider.

4 analysts cover GSK: 1 rate it Buy, 3 Hold and 0 Sell. The average price target is 38.72.